Kamu erişimi zorunlu olan makaleler - Koenraad DebackereDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 2
α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming
PS Liu, H Wang, X Li, T Chao, T Teav, S Christen, G Di Conza, WC Cheng, ...
Nature immunology 18 (9), 985-994, 2017
Zorunlu olanlar: Swiss National Science Foundation, Research Foundation (Flanders), Swiss …
The journal of research, technology and innovation management
M McAdam, K Debackere, K Miller, R McAdam, A Kriz, S Bankins, ...
R&D Management 48, 1, 2018
Zorunlu olanlar: Wellcome Trust, UK Research & Innovation
Bir yerde sunuluyor: 11
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization
M Mazzone, D Dettori, RL de Oliveira, S Loges, T Schmidt, B Jonckx, ...
Cell 136 (5), 839-851, 2009
Zorunlu olanlar: US National Institutes of Health, Research Foundation (Flanders), German …
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity
RL de Oliveira, S Deschoemaeker, AT Henze, K Debackere, ...
Cancer cell 22 (2), 263-277, 2012
Zorunlu olanlar: Research Foundation (Flanders)
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified
K Debackere, L Marcelis, S Demeyer, M Vanden Bempt, N Mentens, ...
Nature communications 12 (1), 3705, 2021
Zorunlu olanlar: Research Foundation (Flanders)
Do material transfer agreements affect the choice of research agendas? The case of biotechnology in Belgium
V Rodriguez, F Janssens, K Debackere, B De Moor
Scientometrics 71 (2), 239-269, 2007
Zorunlu olanlar: Research Foundation (Flanders)
FER and FES tyrosine kinase fusions in follicular T-cell lymphoma
K Debackere, JA van der Krogt, T Tousseyn, JAF Ferreiro, ...
Blood, The Journal of the American Society of Hematology 135 (8), 584-588, 2020
Zorunlu olanlar: Research Foundation (Flanders)
Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma
M Vanden Bempt, K Debackere, S Demeyer, Q Van Thillo, N Meeuws, ...
Blood, The Journal of the American Society of Hematology 140 (23), 2463-2476, 2022
Zorunlu olanlar: Research Foundation (Flanders)
Material transfer agreements and collaborative publication activity: the case of a biotechnology network
V Rodriguez, F Janssens, K Debackere, B De Moor
Research Evaluation 16 (2), 123-136, 2007
Zorunlu olanlar: Research Foundation (Flanders)
Primary mediastinal large B‐cell lymphoma is characterized by large‐scale copy‐neutral loss of heterozygosity
S Tuveri, K Debackere, L Marcelis, N Dierckxsens, J Demeulemeester, ...
Genes, Chromosomes and Cancer 61 (10), 603-615, 2022
Zorunlu olanlar: Research Foundation (Flanders)
On material transfer agreements and visibility of researchers in biotechnology
V Rodriguez, F Janssens, K Debackere, B De Moor
Journal of Informetrics 2 (1), 89-100, 2008
Zorunlu olanlar: Research Foundation (Flanders)
t (9; 12)(q22; p13) ETV6:: SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia.
E Lierman, S Smits, K Debackere, M André, L Michaux, P Vandenberghe
British journal of haematology 200 (5), 2023
Zorunlu olanlar: Research Foundation (Flanders)
Primary mediastinal large B-cell lymphoma is hallmarked by large-scale copy-neutral loss of heterozygosity
S Tuveri, K Debackere, L Marcelis, N Dierckxsens, J Demeulemeester, ...
European Journal Of Human Genetics 31, 525-525, 2023
Zorunlu olanlar: Research Foundation (Flanders)
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir